Key Takeaways
- Recovery taking shape, but not yet in margins: Revenue grew 6% YoY on a 9% volume uptick, yet EBITDA margin stayed at 14.5% because capacity utilization lagged and the salicylic acid plant continued to bleed.
- The salicylic acid bet is all cost, no payoff so far: The plant has been expensing losses for five straight quarters while Chinese dumping crushed prices from ~₹145–₹150 to ₹119–₹120 per kg; management expects a contribution only from Q3 FY26.
- Regulatory doors are reopening at the right moment: USFDA approval regained just as US tariffs on Chinese APIs were announced, and UK MHRA approval came through for the Baddi OSD facility, setting up a regulated-market pivot that could lift both volumes and pricing.
- The capex cycle is peaking, and so is the balance-sheet stretch: Debt held at ₹597 crores despite ~₹150–₹200 crores of annual capex and ~₹170 crores of shareholder payouts over two years; management says debt can fall sharply if no new projects are taken up.
- What to watch next quarter: Whether Sayakha commercializes on time, whether salicylic acid volumes cross 800 tonnes per month, and whether the promised H2 price recovery actually materializes.
Salicylic Acid: The Drag and the Thesis
- A multi-quarter earnings hole: The entire cost of the salicylic acid plant has been expensed out for the last five quarters even though sales have barely begun, creating a direct drag on consolidated EBITDA.
- Chinese dumping as a welcome gift: Chinese competitors reacted to Aarti's commissioning by flooding the Indian market, driving prices down to ₹119–₹120 per kg from a 4–5 year trend of ~₹145–₹150.
- Operational fixes are in progress: Equipment issues prevented smooth continuous production, so the cost-reduction efficiencies that come with scale have not yet been achieved; management says the startup problems have been identified and are being implemented at plant level.
- The margin unlock math: Once the plant reaches 1,500–1,600 tonnes per month and turns profitable, it will add roughly 1% to company-level EBITDA margin; the ramp-up path is 800 tonnes per month very soon, then ~1,600.
- BIS certification as a defensive moat: The company obtained Bureau of Indian Standards certification last year to create a barrier for Chinese producers, and it is approaching the government to file for anti-dumping duty once data is compiled.
- The portfolio hedge: Management is explicit that the rest of the product basket can absorb salicylic acid losses for now, and that derivatives manufacturing is an option if domestic sales of the base product do not work.
Adhish Patil: "Had we been the stand-alone company, manufacturing only salicylic acid, it's going to be a problematic situation for us. But we have such a big product basket that the other products can easily absorb the loss of salicylic acid as of now."
Margin Bridge: Gross Margin Up, EBITDA Stuck
- Gross margin improved 130 bps YoY to 36.8%: The expansion came from normalization of input costs, but the benefit stopped at the gross profit line.
- Low utilization ate the gross margin gain: Had capacity utilization been better, EBITDA margins would have been almost above 14.5% even with current gross margins, per management.
- Manufacturing expenses are sticky but addressable: Manufacturing expenses do not rise proportionally with sales, and the commissioning of the 24.4 MW peak solar project through the Prozeal Green Power JV will reduce power costs, which currently run roughly 3% of revenue.
- The margin ceiling is higher than it looks: In the best possible quarter with high utilizations and solar power online, management sees 16.5% to 17.5% EBITDA margin as achievable, and states that 15% to 20% is possible.
Adhish Patil: "had we had better utilization of the capacity, then probably our EBITDA margins would have been better, I mean, almost above 14.5% even with these gross margins."
Regulatory Re-entry and the US Tariff Tailwind
- USFDA approval regained after the import alert: The official letter arrived in January, and three products are already being referenced in ANDAs; commercial supplies are likely 9 to 12 months away if everything goes well.
- The tariff timing is fortuitous: US tariffs on Chinese APIs were announced right after Aarti got its USFDA approval back, which management believes will push customers solely dependent on China to approve more Indian sources, helping Aarti secure better margins and more approvals.
- Europe will open faster: The import alert had made European customers reluctant to buy from that plant as well; with it lifted, Europe is expected to start much earlier than the US market.
- Formulation subsidiary cleared for regulated markets: The oncology facility received USFDA approval, and the OSD facility received UK MHRA approval; another regulated-market audit is currently ongoing.
- Oncology is a FY28 story: R&D work for 8–10 products should be done by December 2026, followed by filings and 6–9 months of regulatory review before commercial sales can begin; the formulation business is targeted to nearly double to ~₹550–₹600 crores by FY28.
Adhish Patil: "And fortunately, this has come right when we got the USFDA approval back. So definitely, the customers might also feel -- the customers were solely dependent on China, will feel the need to approve more Indian sources."
Volume, Price and the Growth Algorithm
- Volume grew ~9% YoY, price fell ~4.5%: The net result was 4–6% revenue growth, with the price drag concentrated in the first half; management expects negative price variation of minus 4% to minus 6% in H1 FY26, which should disappear from H2 onwards.
- Volume growth guidance is 15% CAGR: Management targets roughly 15% year-on-year volume growth for both FY26 and FY27, with value growth of 5–6% in H1 FY26, ~10% or more in H2, and 10–15% in FY27 based on prevailing prices.
- API and formulation mix is inherently volatile: A couple of percentage points of variation quarter to quarter reflects tender timing and demand fluctuations in the formulation business, not a structural shift.
- Formulation exports are scaling: The formulation business grew 14% YoY to ₹80 crores, with 57% from exports, and commercial operations have commenced in Latin America and a few African markets.
Capex Cycle: Heavy Spend, Long Payback
- Sayakha greenfield started trial production: The plant is set up mainly for backward integration into anti-diabetic products and their intermediates, largely for internal requirements; commercialization is targeted for Q2 but may slip to Q3 if issues arise.
- Tarapur API facility is approved and expanding: The recently USFDA-approved site is now attracting regulated customer audits, and adjoining land parcels have been acquired for more production blocks that will take 12 to 24 months to commission.
- Capex is 80–85% growth-oriented: Roughly half goes to formulation R&D for oncology and non-oncology regulated-market products; the rest covers brownfield expansion in antifungals, cardiovascular products, a new block for the USFDA facility, and anti-diabetic therapy expansion.
- Full benefit arrives only by FY28: Management estimates it will take around three years for the full benefit of current capacity expansions to translate into financials, as greenfield assets ramp toward optimum utilization.
- Debt can fall sharply if capex pauses: At ₹597 crores, debt has been held steady despite heavy spending and ~₹170 crores of shareholder payouts over two years; without new projects, the debt level can come down drastically, and management sees 0.4 to 0.7 as a fair debt-to-equity range.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth | ~15% YoY volume growth | FY26 and FY27 |
| Value growth | 5–6% in H1, ~10% or more in H2 | FY26 |
| Value growth | 10–15% value growth | FY27 |
| Price variation | Negative 4–6% YoY in H1, neutral from H2 | FY26 |
| EBITDA margin | 15–16% achievable if everything goes right; last quarter of FY26 may attempt it | FY27 annual; Q4 FY26 trial |
| Salicylic acid contribution | Begin contributing to financials | Q3 FY26 |
| Salicylic acid ramp-up | 800 tonnes/month very soon, then ~1,600 tonnes/month | No date; breakeven at 1,500–1,600 tonnes |
| Sayakha commercialization | Trial production started; targeting Q2 | Q2 FY26, may slip to Q3 |
| US commercial supplies | Three products expected to launch; 9–12 months to commercial supplies | ~9–12 months from Q1 FY26 |
| Formulation revenue target | ~₹550–₹600 crores | FY28 |
| Oncology R&D completion | 8–10 products | December 2026 |
| New production blocks (Tarapur) | Commissioning | 12–24 months |
| Full capex benefit | Optimum utilization of all greenfield capex | ~FY28 |
| Solar project | Lower long-term power cost once fully operational | Commissioning in process |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Total revenue | ₹591 cr, +6% YoY |
| Gross profit margin | 36.8%, +130 bps YoY |
| EBITDA | ₹74 cr, +12% YoY |
| EBITDA margin | 12.6% |
| API business revenue growth | +5% YoY |
| Formulation business revenue | ₹80 cr, +14% YoY |
| Formulation export share | 57% of formulation revenue |
| Volume growth (standalone) | ~9% YoY |
| Negative price variation | ~4.5% YoY |
| Capex incurred | ₹48.5 cr (consolidated) |
| FY26 capex guidance | ₹150 cr to ₹200 cr |
| Net debt | ~₹597 cr (consolidated), 56% long-term, 44% working capital |
| Debt-to-equity ratio | ~0.42 to 0.43 |
| Salicylic acid current output | below 200 tonnes per month |
| Salicylic acid ramp-up target | 800 tonnes per month near-term, expanding to ~1,600 tonnes per month |